Eagle Asset Management Inc. Has $2.42 Million Position in Perspective Therapeutics, Inc. (NYSE:CATX)

Eagle Asset Management Inc. lessened its stake in shares of Perspective Therapeutics, Inc. (NYSE:CATX) by 24.9% in the third quarter, according to the company in its most recent filing with the SEC. The fund owned 181,467 shares of the company’s stock after selling 60,212 shares during the quarter. Eagle Asset Management Inc. owned about 0.27% of Perspective Therapeutics worth $2,423,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the stock. nVerses Capital LLC bought a new position in Perspective Therapeutics in the 3rd quarter valued at about $57,000. US Bancorp DE increased its stake in shares of Perspective Therapeutics by 142.7% during the third quarter. US Bancorp DE now owns 6,576 shares of the company’s stock worth $88,000 after purchasing an additional 3,866 shares during the period. Victory Capital Management Inc. acquired a new stake in Perspective Therapeutics during the 2nd quarter worth approximately $117,000. Point72 DIFC Ltd bought a new stake in Perspective Therapeutics in the 2nd quarter valued at $118,000. Finally, Intech Investment Management LLC acquired a new position in Perspective Therapeutics in the 3rd quarter valued at $137,000. Institutional investors own 54.66% of the company’s stock.

Wall Street Analyst Weigh In

CATX has been the subject of a number of research reports. Royal Bank of Canada dropped their target price on Perspective Therapeutics from $25.00 to $16.00 and set an “outperform” rating for the company in a report on Monday. Wedbush reiterated an “outperform” rating and issued a $11.00 price objective (down previously from $20.00) on shares of Perspective Therapeutics in a research note on Thursday, November 21st. Cantor Fitzgerald restated an “overweight” rating on shares of Perspective Therapeutics in a research report on Monday, September 9th. Bank of America downgraded shares of Perspective Therapeutics from a “buy” rating to a “neutral” rating and dropped their price target for the company from $24.00 to $5.00 in a research report on Monday. Finally, Oppenheimer reduced their price target on Perspective Therapeutics from $22.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. Based on data from MarketBeat.com, Perspective Therapeutics currently has an average rating of “Moderate Buy” and a consensus price target of $15.14.

Perspective Therapeutics Trading Up 6.3 %

Shares of NYSE:CATX opened at $3.69 on Tuesday. Perspective Therapeutics, Inc. has a 1 year low of $2.28 and a 1 year high of $19.05. The company has a 50 day moving average price of $11.33.

Perspective Therapeutics (NYSE:CATX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative return on equity of 27.40% and a negative net margin of 4,096.66%. The company had revenue of $0.37 million for the quarter. As a group, equities analysts predict that Perspective Therapeutics, Inc. will post -0.86 EPS for the current fiscal year.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.